Insights of Pharmatech, 1 (2), 2025, 26-28.
Available at amepurvapub.com

Insights of Pharmatech
Official Journal of Amepurva Forum

REVIEW

Smart Pills in Pharmacy: Monitoring Adherence and Drug Response Through Ingestible Tech

Bandoo C. Chatale
MET Institute of Pharmacy, MET Complex, Bandra Reclamation, Bandra (West), Mumbai 400050, India
**Corresponding author: banduchatale89@gmail.com*
Received on: 06/042025 Accepted on: 20/05/2025 Published on: 30/06/2025

ABSTRACT

Smart pills, or ingestible sensors, represent a transformative innovation in pharmaceutical care by enabling real-time monitoring of patient adherence and physiological responses to medications. This review explores the development, mechanisms, applications, and challenges of smart pill technology, with a focus on its role in enhancing medication adherence, optimizing therapeutic outcomes, and integrating with digital health ecosystems. The paper also discusses regulatory, ethical, and economic considerations, while highlighting future directions for clinical implementation.

KEYWORDS: Smart Pills, Medication Adherence, Ingestible Sensors, Digital Health Technology, Personalized Medicine

INTRODUCTION

Medication non-adherence is widely recognized as one of the most pressing and costly challenges in modern healthcare. Studies consistently report that nearly 50% of patients with chronic conditions fail to take their medications as prescribed. This includes skipping doses, delaying refills, prematurely discontinuing treatment, or taking the incorrect dosage. The consequences of such behaviors are far-reaching. On an individual level, poor adherence leads to disease progression, reduced functional abilities, diminished quality of life, and in many cases, preventable complications or death. On a systemic level, non-adherence places an enormous financial burden on healthcare systems worldwide, with estimated costs reaching hundreds of billions of dollars annually due to increased hospital admissions, emergency visits, and the need for more intensive care interventions.(1-2)

Traditional adherence assessment methods have long been used in clinical settings, yet they offer limited reliability. Common techniques such as self-report questionnaires, physician interviews, pharmacy refill tracking, and manual pill counts are often prone to bias and error. Patients may unintentionally misremember their medication use, or in some cases, intentionally provide inaccurate information due to embarrassment, mistrust, or fear of judgment. Moreover, these methods generally do not provide real-time data, making it difficult for healthcare providers to intervene promptly when a problem arises.(3)

This is where smart pill technology presents a compelling alternative. By embedding microscopic, biocompatible sensors within a medication capsule, these devices can detect the exact moment the pill is swallowed and begins interacting with the digestive system. Once activated by gastric fluids, the sensor sends a signal to a wearable patch or device, which then transmits the data to a connected smartphone app or secure digital platform. This real-time, objective evidence of ingestion removes the guesswork from adherence monitoring and gives healthcare professionals a much clearer picture of patient behavior.(4)

In addition to confirming whether a medication was taken, some smart pill systems are designed to gather additional physiological data—such as heart rate, body temperature, or other biomarkers—which can help clinicians assess the patient's response to the drug. This creates opportunities not only for improved adherence tracking but also for optimizing dosages and tailoring treatment strategies based on individual responses. In chronic illnesses such as schizophrenia, HIV, diabetes, and cardiovascular disease—where adherence is directly linked to outcomes—this level of precision could significantly improve disease management, reduce complications, and even save lives.(5)

By bridging the gap between medication delivery and patient behavior, smart pills represent more than just a technological novelty; they signal a shift toward a more data-driven, personalized model of pharmaceutical care. They hold particular promise in high-risk populations, such as the elderly, individuals with cognitive impairments, or patients with complex medication regimens, where the consequences of missed doses can be particularly severe. As such, this innovation has the potential not only to enhance individual health outcomes but also to transform the broader landscape of medication management across diverse healthcare systems.(6)

OVERVIEW OF SMART PILL TECHNOLOGY

Smart pills are ingestible electronic sensors embedded within

capsules or tablets that communicate with external devices. Upon ingestion, the sensor activates in the stomach by reacting with gastric fluids. It then transmits data to a wearable patch or receiver, which forwards the information to a mobile application or cloud-based platform for monitoring. The core components include a biocompatible, battery-free sensor chip, the ingestible capsule itself, a wearable receiver such as a patch or belt, and software for data visualization and analysis. These components work together to provide seamless tracking of drug intake in real-time.(7-8)

KEY APPLICATIONS

Smart pill technology has multiple applications across healthcare. One of the primary uses is adherence monitoring, where real-time tracking of medication intake supports better disease management. This is especially critical in diseases like tuberculosis, schizophrenia, HIV, and hypertension, where missed doses can lead to severe complications or drug resistance. The data collected also helps clinicians tailor dosages and schedules based on the patient's response patterns, thereby optimizing therapeutic outcomes. In clinical trials, smart pills offer an accurate way to monitor participant compliance, ensuring higher data integrity and reliability.(8-9)

CASE STUDIES AND CURRENT PRODUCTS

One notable example is Abilify MyCite, the first FDA-approved digital pill designed to monitor ingestion in patients with schizophrenia and bipolar disorder. This product incorporates an ingestible sensor within the antipsychotic medication aripiprazole. Another pioneer in this field, Proteus Digital Health, developed sensor-based adherence technology and initiated significant advancements in the space. Although commercial challenges led to the company's closure, its foundational technology continues to influence ongoing developments.(10)

ADVANTAGES

Smart pills offer several advantages over traditional methods of adherence monitoring. They significantly improve medication compliance by providing objective, real-time data. This reduces reliance on self-reporting, which can often be inaccurate. The continuous data stream enhances patient engagement, especially when integrated with user-friendly mobile applications. Moreover, smart pills have the potential to reduce hospital readmissions, lower healthcare costs, and enable more precise treatment regimens through data-driven insights.(11-12)

CHALLENGES AND LIMITATIONS

Despite their potential, smart pills face several challenges. Privacy and data security are major concerns, given the sensitive nature of health data being transmitted and stored. High development and implementation costs can limit accessibility, particularly in resource-constrained settings. Patient acceptance is another barrier, as psychological, cultural, and ethical factors may influence willingness to use such technology. Technical reliability issues, including sensor activation and data accuracy, must also be addressed to ensure widespread adoption.(13)

REGULATORY AND ETHICAL CONSIDERATIONS

Regulatory frameworks for digital therapeutics are still evolving. Agencies like the FDA and EMA have started outlining pathways for approval and post-marketing surveillance. However, clear guidelines regarding data privacy, patient consent, and digital health integration are still needed. Ethical concerns also arise, particularly regarding surveillance, autonomy, and the potential for misuse of adherence data. Ensuring transparency and patient education will be crucial for ethical implementation.(14, 5)

FUTURE PERSPECTIVES

The future of smart pill technology is promising. Integrating these systems with artificial intelligence could allow for predictive analytics and personalized intervention strategies. The development of multi-analyte sensors capable of measuring parameters such as glucose levels or stomach pH could expand their utility. Furthermore, there is growing interest in applying this technology to personalized nutrition and wellness. For widespread adoption, especially in low- and middle-income countries, scalable and cost-effective models need to be developed.(15)

CONCLUSION

Smart pills represent a promising frontier in digital health and pharmacy. While technical, ethical, and financial barriers remain, the continued evolution of ingestible technology holds immense potential to revolutionize medication adherence, therapeutic monitoring, and patient-centered care. As technology becomes more integrated with healthcare systems, smart pills could play a pivotal role in shaping the future of personalized medicine.

REFERENCES

1. Kardas P. From non-adherence to adherence: can inno-

vative solutions resolve a longstanding problem? Eur J Intern Med. 2024;119:6–12.

2. Al Meslamani AZ. Policy solutions for medication non-adherence: what can governments do? Expert Rev Pharmacoecon Outcomes Res. 2024;24:777–81.
3. Choo PW, Rand CS, Inui TS, Lee M-LT, Cain E, Cordeiro-Breault M, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care. 1999;37:846–57.
4. Root L. High-Tech Adherence: Incorporating Smart Pill Technology Into Wellness Programs. Quinnipiac Heal LJ. 2016;19:121.
5. Avery M, Liu D. Bringing smart pills to market: FDA regulation of ingestible drug/device combination products. Food Drug LJ. 2011;66:329.
6. Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, et al. Advancing precision medicine: a review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. Pharmaceutics. 2024;16:332.
7. Cummins G. Smart pills for gastrointestinal diagnostics and therapy. Adv Drug Deliv Rev. 2021;177:113931.
8. Minaam DSA, Abd-ELfattah M. Smart drugs: Improving healthcare using smart pill box for medicine reminder and monitoring system. Futur Comput Informatics J. 2018;3:443–56.
9. Faisal S, Samoth D, Aslam Y, Patel H, Park S, Baby B, et al. Key features of smart medication adherence products: updated scoping review. JMIR aging. 2023;6:e50990.
10. Cosgrove L, Morrill Z, Karter JM. Digital aripiprazole as a human technology. Econ Soc. 2021;50:359–73.
11. Aldeer M, Javanmard M, Martin RP. A review of medication adherence monitoring technologies. Appl Syst Innov. 2018;1:14.
12. Al Shammari YH, Al Shammari HA, Barak TM Bin, Alharbi BS, Alshammari ST, Alnais SA, et al. Smart Pills: the Future of Adherence Monitoring. Int J Health Sci (Qassim). 3:1–15.
13. Goffredo R, Accoto D, Guglielmelli E. Swallowable smart pills for local drug delivery: present status and future perspectives. Expert Rev Med Devices. 2015;12:585–99.
14. Klugman CM, Dunn LB, Schwartz J, Cohen IG. The ethics of smart pills and self-acting devices: autonomy, truth-telling, and trust at the dawn of digital medicine. Am J Bioeth. 2018;18:38–47.
15. Raikar AS, Kumar P, Raikar G (Vedant) S, Somnache SN. Advances and challenges in IoT-based smart drug delivery systems: a comprehensive review. Appl Syst Innov. 2023;6:62.